SCHEDULE: Thomas Satterfield Jr. Discloses 9% Stake in enVVeno Medical

Thomas A. Satterfield, Jr. has disclosed a 9.0% beneficial ownership stake in enVVeno Medical Corporation, totaling 1,822,500 shares.

Summary

• Thomas A. Satterfield, Jr. has filed a Schedule 13G, reporting beneficial ownership of 1,822,500 shares of enVVeno Medical Corporation's Common Stock.
• This aggregate amount represents 9.0% of the company's outstanding common stock, based on 20,216,176 shares as of October 28, 2025.
• Mr. Satterfield holds sole voting and dispositive power over 165,000 shares.
• He holds shared voting and dispositive power over 1,657,500 shares.
• The shares under shared power include 400,000 shares held by Tomsat Investment & Trading Co., Inc., a corporation wholly owned by Mr. Satterfield, and 1,250,000 shares held by Caldwell Mill Opportunity Fund, LLC, a fund managed by an entity where Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager.
• Additionally, Mr. Satterfield has a limited power of attorney for voting and disposition purposes over 7,500 shares held by Rebecca A. Satterfield, who retains the right to receive proceeds from the sale of her shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A 13G filing is primarily a factual disclosure of ownership, which is inherently neutral. However, a significant stake by an individual investor can be interpreted as a vote of confidence, hence a slightly positive lean.

Positives

• A significant beneficial ownership stake by an individual investor like Thomas A. Satterfield, Jr. can signal confidence in the company's future prospects.
• The disclosure of a 9.0% stake indicates a substantial long-term interest from a sophisticated investor.

Negatives

• NA

Risks

• The concentration of a significant portion of voting and dispositive power (9.0%) in a single individual and entities related to them could potentially influence corporate decisions, although the filing states the shares were not acquired for the purpose of changing or influencing control.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant ownership and does not provide specific industry context. However, a substantial stake by an individual investor in a medical corporation could be viewed as a positive signal within the healthcare and medical device sector, indicating belief in the company's technology or market position.

Related Party Transactions

• 400,000 shares of Common Stock are held by Tomsat Investment & Trading Co., Inc., a corporation wholly owned by Mr. Satterfield and of which he serves as President.
• 1,250,000 shares of Common Stock are held by Caldwell Mill Opportunity Fund, LLC, a fund managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager.
• Mr. Satterfield has a limited power of attorney for voting and disposition purposes with respect to 7,500 shares of Common Stock held by Rebecca A. Satterfield.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a prominent individual investor may instill confidence among existing shareholders and attract new investors.
• Management: Management may need to consider the views of a significant shareholder, especially given the certification regarding potential nomination activities under Rule 14a-11.

Key Dates

Recommendation

A Schedule 13G filing primarily discloses a significant ownership stake and does not provide operational or financial performance details. While a 9.0% stake by an individual investor can be seen as a positive signal of confidence, it is insufficient on its own to warrant a 'buy' or 'sell' recommendation. A 'hold' recommendation is appropriate as investors would need to combine this information with the company's financial reports, strategic initiatives, and market conditions to make an informed investment decision.

Keywords

enVVeno Medical Corporation, Thomas A. Satterfield Jr., Schedule 13G, Beneficial Ownership, Common Stock, Shareholder, Investment, Medical Devices